

Yee Chao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276646/publications.pdf>

Version: 2024-02-01

178
papers

6,745
citations

147726

31
h-index

74108

75
g-index

180
all docs

180
docs citations

180
times ranked

8378
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2461-2471.	6.3	1,749
2	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
3	Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery. <i>Annals of Surgical Oncology</i> , 2003, 10, 355-362.	0.7	201
4	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	1.8	180
5	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	2.7	155
6	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4004-4004.	0.8	149
7	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1066-1076.	5.1	130
8	The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in <sc>A</sc>sian patients with hepatocellular carcinoma: Final results of the <sc>START</sc> trial. <i>International Journal of Cancer</i> , 2015, 136, 1458-1467.	2.3	109
9	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. <i>Journal of Hepatology</i> , 2012, 56, 1097-1103.	1.8	91
10	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. <i>Oncotarget</i> , 2015, 6, 18162-18173.	0.8	90
11	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
12	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
13	Randomized, openâ€“label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 774-784.	3.6	77
14	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
15	Clinical significance of circulating plasma DNA in gastric cancer. <i>International Journal of Cancer</i> , 2016, 138, 2974-2983.	2.3	68
16	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2-2.	0.8	64
17	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	2.7	61
18	Mutations in PI3K/AKT pathway genes and amplifications of <i>PIK3CA</i> are associated with patterns of recurrence in gastric cancers. <i>Oncotarget</i> , 2016, 7, 6201-6220.	0.8	61

#	ARTICLE	IF	CITATIONS
19	A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1704-1712.	1.9	58
20	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 480-490.	4.2	57
21	A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. <i>Pharmaceutical Research</i> , 1999, 16, 997-1002.	1.7	56
22	Phase II study of flutamide in the treatment of hepatocellular carcinoma. <i>Cancer</i> , 1996, 77, 635-639.	2.0	54
23	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 874-883.	0.7	51
24	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 307-311.	1.1	50
25	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2405-2413.	3.2	48
26	Update on treatment of gastric cancer. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 345-353.	0.6	45
27	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	2.7	45
28	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
29	Activation of MAD 2 checkpoint and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2000, 5, 235-241.	2.2	38
30	PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4146-TPS4146.	0.8	38
31	Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 321-330.	1.9	37
32	A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4014-4014.	0.8	36
33	Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 581-589.	1.4	35
34	Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan. <i>Biology</i> , 2021, 10, 334.	1.3	33
35	<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
36	A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 637-642.	1.1	31

#	ARTICLE	IF	CITATIONS
37	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. <i>International Journal of Biological Sciences</i> , 2016, 12, 1523-1532.	2.6	31
38	Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. <i>Hepatology International</i> , 2013, 7, 883-892.	1.9	30
39	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. <i>Medicine (United States)</i> , 2015, 94, e688.	0.4	30
40	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021, 10, 275-284.	4.2	29
41	Using salvage Boron Neutron Capture Therapy (BNCT) for recurrent malignant brain tumors in Taiwan. <i>Applied Radiation and Isotopes</i> , 2020, 160, 109105.	0.7	28
42	Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. <i>Liver Cancer</i> , 2021, 10, 629-640.	4.2	27
43	High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 454-459.	0.6	26
44	Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 277-281.	1.4	25
45	<i>Helicobacter pylori</i> -induced chronic inflammation causes telomere shortening of gastric mucosa by promoting PARP-1-mediated non-homologous end joining of DNA. <i>Archives of Biochemistry and Biophysics</i> , 2016, 606, 90-98.	1.4	25
46	Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without <i>Helicobacter pylori</i> Infection. <i>Oncologist</i> , 2019, 24, e845-e853.	1.9	24
47	The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery. <i>Cancers</i> , 2020, 12, 1517.	1.7	24
48	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 165-178.	4.2	23
49	Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001. <i>Clinical Cancer Research</i> , 2021, 27, 3649-3660.	3.2	23
50	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 439-450.	4.2	21
51	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. <i>Scientific Reports</i> , 2016, 6, 25369.	1.6	21
52	Evolutionary Learning-Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma after Resection. <i>Liver Cancer</i> , 2021, 10, 572-582.	4.2	21
53	Survival outcomes of management in metastatic gastric adenocarcinoma patients. <i>Scientific Reports</i> , 2021, 11, 23142.	1.6	21
54	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. <i>Hepatology International</i> , 2012, 6, 753-762.	1.9	20

#	ARTICLE	IF	CITATIONS
55	PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1785-1794.	1.2	20
56	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	2.0	20
57	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 218-229.	0.8	19
58	Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6940.	1.8	19
59	Comparative study of the 7th and 8th AJCC editions for gastric cancer patients after curative surgery. <i>PLoS ONE</i> , 2017, 12, e0187626.	1.1	18
60	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	1.4	18
61	The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. <i>Cancers</i> , 2020, 12, 2318.	1.7	18
62	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4017-4017.	0.8	18
63	Advances in Laparoscopic and Robotic Gastrectomy for Gastric Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 13-17.	0.9	17
64	A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. <i>EJNMMI Research</i> , 2019, 9, 46.	1.1	17
65	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	0.8	17
66	Metallic Stent Expansion Rate at Day One Predicts Stent Patency in Patients with Gastric Outlet Obstruction. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1286-1294.	1.1	16
67	A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4108-4108.	0.8	16
68	Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2022, 166, 208-218.	1.3	16
69	Akt phosphorylates myc-associated zinc finger protein (MAZ), releases P-MAZ from the p53 promoter, and activates p53 transcription. <i>Cancer Letters</i> , 2016, 375, 9-19.	3.2	15
70	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1534-1542.	1.9	15
71	Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. <i>Oncotarget</i> , 2015, 6, 23594-23608.	0.8	15
72	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 799-806.	1.1	14

#	ARTICLE	IF	CITATIONS
73	Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 140-146.	0.6	14
74	Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report. <i>American Journal of Gastroenterology</i> , 2017, 112, 659-660.	0.2	14
75	Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 125-133.	0.8	14
76	Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. <i>Scientific Reports</i> , 2020, 10, 18375.	1.6	14
77	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , 2020, 25, e1280-e1285.	1.9	14
78	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	1.1	14
79	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. <i>Investigational New Drugs</i> , 2022, 40, 789-797.	1.2	14
80	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 218.	1.7	13
81	Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 620361.	1.3	12
82	Differential prognoses among male and female patients with hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 554-565.	0.6	11
83	The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 141-147.	0.6	10
84	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GE) cancer (ATTRACTION-2): Three-year update data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 383-383.	0.8	10
85	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1599-1607.	1.0	9
86	Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array. <i>Clinical Epigenetics</i> , 2019, 11, 154.	1.8	9
87	The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAS and MSI Status. <i>Cancers</i> , 2020, 12, 551.	1.7	9
88	Effect of Primary Tumor Location on Postmetastectomy Survival in Patients with Colorectal Cancer Liver Metastasis. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 650-661.	0.9	9
89	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
90	KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4018-4018.	0.8	9

#	ARTICLE	IF	CITATIONS
91	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. Journal of Clinical Oncology, 2020, 38, 4523-4523.	0.8	9
92	A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan. PLoS ONE, 2015, 10, e0139748.	1.1	9
93	Genetic alterations in gastric cancer patients according to sex. Aging, 2021, 13, 376-388.	1.4	9
94	Expression profile-driven discovery of AURKA as a treatment target for liposarcoma. International Journal of Oncology, 2019, 55, 938-948.	1.4	9
95	Life-threatening haemorrhage from a sternal metastatic hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 684-687.	1.4	8
96	Concurrence of UGT1A Polymorphism and End-Stage Renal Disease Leads to Severe Toxicities of Irinotecan in a Patient with Metastatic Colon Cancer. Tumori, 2011, 97, 243-247.	0.6	8
97	Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 28-34.	0.6	8
98	The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 136-143.	0.6	8
99	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 144-150.	0.6	8
100	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers, 2021, 13, 4325.	1.7	8
101	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. Journal of Global Oncology, 2018, 4, 1-12.	0.5	7
102	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. Journal of the Formosan Medical Association, 2020, 119, 238-246.	0.8	7
103	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist, 2020, 25, e782-e788.	1.9	7
104	The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. British Journal of Cancer, 2021, 125, 816-825.	2.9	7
105	Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 339-339.	0.8	7
106	Lenvatinib for the treatment of HCC: A single institute experience.. Journal of Clinical Oncology, 2019, 37, e15611-e15611.	0.8	7
107	The clinicopathological characteristics and genetic alterations between younger and older gastric cancer patients with curative surgery. Aging, 2020, 12, 18137-18150.	1.4	7
108	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS ONE, 2017, 12, e0188552.	1.1	6

#	ARTICLE	IF	CITATIONS
109	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, 4143-4143.	0.8	6
110	PRKDC: A new candidate for checkpoint blockade immunotherapy?. Journal of Clinical Oncology, 2017, 35, 3022-3022.	0.8	6
111	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. Journal of Clinical Oncology, 2020, 38, TPS3145-TPS3145.	0.8	6
112	Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. Journal of the Chinese Medical Association, 2022, 85, 42-50.	0.6	6
113	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 4032-4032.	0.8	6
114	Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheres. Journal of the Formosan Medical Association, 2021, 120, 1127-1136.	0.8	5
115	Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer, 1996, 77, 635-639.	2.0	5
116	Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.. Journal of Clinical Oncology, 2014, 32, TPS4148-TPS4148.	0.8	5
117	RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapyâ€”An age-group analysis.. Journal of Clinical Oncology, 2015, 33, 11-11.	0.8	5
118	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 237-237.	0.8	5
119	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. Journal of Clinical Oncology, 2020, 38, 526-526.	0.8	5
120	Determinants of Survival and Post-Progression Outcomes by Sorafenibâ€™Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 2014.	1.7	5
121	Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. Journal of the Chinese Medical Association, 2022, 85, 679-686.	0.6	5
122	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Scientific Reports, 2022, 12, 8343.	1.6	5
123	Outcome for selfâ€™expandable metal stents inâ€™patientsâ€™with malignant gastroduodenal obstruction: A single center experience. Advances in Digestive Medicine, 2014, 1, 1-8.	0.1	4
124	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. Journal of the Chinese Medical Association, 2018, 81, 593-598.	0.6	4
125	The clinicopathological characteristics and prognosis of patients with node-positive gastric cancer after curative surgery. Journal of the Chinese Medical Association, 2020, 83, 751-755.	0.6	4
126	Comparison of the Long-term Outcome Between Billroth-I and Roux-en-Y Reconstruction Following Distal Gastrectomy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 1955-1961.	0.9	4

#	ARTICLE	IF	CITATIONS
127	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1581-1590.	0.8	4
128	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3-3.	0.8	4
129	Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16627-e16627.	0.8	4
130	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. <i>American Journal of Cancer Research</i> , 2021, 11, 3711-3725.	1.4	4
131	Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1955-1968.	1.6	4
132	Bifocal lesions have a poorer treatment outcome than a single lesion in adult patients with intracranial germinoma. <i>PLoS ONE</i> , 2022, 17, e0264641.	1.1	4
133	Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. <i>PLoS ONE</i> , 2022, 17, e0268920.	1.1	4
134	Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 837-849.	1.8	3
135	Identification of phenothiazine as an ETV1-targeting agent in gastrointestinal stromal tumors using the Connectivity Map. <i>International Journal of Oncology</i> , 2019, 55, 536-546.	1.4	3
136	Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 446-453.	0.6	3
137	Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16138-e16138.	0.8	3
138	TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4143-TPS4143.	0.8	3
139	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8-8.	0.8	3
140	Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series. <i>Life</i> , 2022, 12, 566.	1.1	3
141	Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. <i>Oncology Letters</i> , 2018, 16, 3070-3082.	0.8	2
142	Association of gut microbiota and metabolites with tumor response to immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16165-e16165.	0.8	2
143	Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. <i>Scientific Reports</i> , 2021, 11, 15370.	1.6	2
144	A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4030-4030.	0.8	2

#	ARTICLE	IF	CITATIONS
145	A phase II study of ADI-PEG 20 and FOLFOX6 in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, TPS477-TPS477.	0.8	2
146	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. Journal of Clinical Oncology, 2020, 38, 4587-4587.	0.8	2
147	The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 917-928.	1.8	1
148	Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population. Journal of the Chinese Medical Association, 2018, 81, 423-428.	0.6	1
149	Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. Journal of the Chinese Medical Association, 2020, 83, 624-625.	0.6	1
150	Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. Frontiers in Oncology, 2021, 11, 632609.	1.3	1
151	Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study. , 2021, , .		1
152	Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells. Biochemical and Biophysical Research Communications, 2021, 582, 137-143.	1.0	1
153	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15656-e15656.	0.8	1
154	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, 90-90.	0.8	1
155	Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).. Journal of Clinical Oncology, 2013, 31, TPS4161-TPS4161.	0.8	1
156	A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial.. Journal of Clinical Oncology, 2015, 33, 4024-4024.	0.8	1
157	A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. Journal of Clinical Oncology, 2019, 37, TPS176-TPS176.	0.8	1
158	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).. Journal of Clinical Oncology, 2019, 37, 4101-4101.	0.8	1
159	The clinicopathological characteristics and genetic alterations of gastric cancer patients according to the Lauren classification. International Surgery, 0, , .	0.0	1
160	Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210994.	1.4	1
161	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, TPS4172-TPS4172.	0.8	1
162	Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 95-100.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	0.8	0
164	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	0.8	0
165	Evaluation of transcatheter arterial chemoembolization (TACE) plus sorafenib in Chinese patients with unresectable hepatocellular carcinoma: A subgroup analysis of START trial.. Journal of Clinical Oncology, 2012, 30, e14605-e14605.	0.8	0
166	Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial.. Journal of Clinical Oncology, 2014, 32, 267-267.	0.8	0
167	The risk of second primary malignancy among male breast cancer patients: A population-based study.. Journal of Clinical Oncology, 2014, 32, 1594-1594.	0.8	0
168	Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. Journal of Clinical Oncology, 2015, 33, 4074-4074.	0.8	0
169	Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluorouracil or capecitabine).. Journal of Clinical Oncology, 2017, 35, e15671-e15671.	0.8	0
170	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, e15127-e15127.	0.8	0
171	Genomic profiling for unfavorable carcinoma of unknown primary patients.. Journal of Clinical Oncology, 2019, 37, e13140-e13140.	0.8	0
172	A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.. Journal of Clinical Oncology, 2019, 37, e15518-e15518.	0.8	0
173	Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, 3115-3115.	0.8	0
174	DNA damage and repair gene panel as a biomarker of immune checkpoint inhibitor response.. Journal of Clinical Oncology, 2020, 38, e15052-e15052.	0.8	0
175	362 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma. , 2021, 9, A389-A389.		0
176	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, TPS488-TPS488.	0.8	0
177	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. American Journal of Cancer Research, 2021, 11, 5526-5542.	1.4	0
178	Role of organ-specific response to immune checkpoint inhibitor in survival for advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, e16172-e16172.	0.8	0